MiNK Therapeutics, Inc.
INKT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001840229
No open-market purchases or sales by MiNK Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $2.39M in total; no superinvestor holds it.
13F holders, Q2 2025
Institutional positions in MiNK Therapeutics, Inc. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 19
- +2 vs. Q1 2025
- Shares held
- 61.9K
- −1.05K (−1.7%) vs. Q1 2025
- Total value
- $460.8K
- −$83.4K (−15.3%) vs. Q1 2025
- New holders
- 3
- 5 more added
- Sold out
- 1
- 5 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting INKT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 27 | $2.39M |
| Q1 2026 | 23 | $1.34M |
| Q4 2025 | 25 | $1.71M |
| Q3 2025 | 18 | $1.28M |
| Q2 2025 | 19 | $460.8K |
| Q1 2025 | 17 | $544.2K |
| Q4 2024 | 23 | $564.9K |
| Q3 2024 | 26 | $632.3K |
| Q2 2024 | 31 | $847.8K |
| Q1 2024 | 34 | $848.1K |
| Q4 2023 | 36 | $1.05M |
| Q3 2023 | 36 | $800.0K |
| Q2 2023 | 45 | $3.10M |
| Q1 2023 | 12 | $1.15M |
| Q4 2022 | 16 | $1.70M |
| Q3 2022 | 11 | $1.00M |
| Q2 2022 | 13 | $504.0K |
| Q1 2022 | 25 | $1.76M |
| Q4 2021 | 21 | $5.96M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding MiNK Therapeutics, Inc.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Jones Financial Companies LLLP | 1 | $7 | 0.00% | 00.0% | Unchanged |
| Key Financial Inc | 4 | $30 | 0.00% | +4 | New |
| JPMorgan Chase & Co | 12 | $89 | 0.00% | −18−60.0% | Reduced |
| Clearstead Advisors, LLC | 14 | $104 | 0.00% | 00.0% | Unchanged |
| Game Plan Financial Advisors, LLC | 16 | $118 | 0.00% | 00.0% | Unchanged |
| Northwestern Mutual Wealth Management Co | 19 | $140 | 0.00% | +1+5.6% | Added |
| Morgan Stanley | 22 | $163 | 0.00% | −2−8.3% | Reduced |
| BNP Paribas Arbitrage, SA | 26 | $192 | 0.00% | +3+13.0% | Added |
| Raymond James Financial Inc | 32 | $236 | 0.00% | +32 | New |
| Advisor Group Holdings, Inc. | 120 | $883 | 0.00% | −118−49.6% | Reduced |
| Covestor Ltd | 131 | $1.00K | 0.00% | +27+26.0% | Added |
| UBS Group AG | 284 | $2.10K | 0.00% | 00.0% | Unchanged |
| Total Investment Management Inc | 500 | $3.69K | 0.00% | +500 | New |
| Bank of America Corp | 568 | $4.20K | 0.00% | −189−25.0% | Reduced |
| Wells Fargo & Company | 849 | $6.27K | 0.00% | +1+0.1% | Added |
| BlackRock, Inc. | 7,421 | $54.8K | 0.00% | −1,357−15.5% | Reduced |
| Geode Capital Management, LLC | 11,492 | $86.0K | 0.00% | +238+2.1% | Added |
| Longbow Finance SA | 16,667 | $123.1K | 0.01% | 00.0% | Unchanged |
| Vanguard Group Inc | 23,744 | $177.6K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −172−100.0% | Sold out |